Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity.
Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity.
复制标题
四价人乳头瘤病毒疫苗的延迟给药间隔不会降低抗体亲合力。
DOI：
10.1080/21645515.2019.1706410
复制
发表时间：
2020
影响因子：
4.8
通讯作者：
Panicker,Gitika
中科院分区：
文献类型：
--
作者：
Brady,AllisonM;Walter,EmmanuelB;Markowitz,LauriE;Unger,ElizabethR;Panicker,Gitika
四价HPV疫苗(4vHPV)最初被推荐为三剂系列(0/2/6个月)，尽管完成该系列的延迟经常发生。我们之前发现，与按时服药相比，女孩延迟服药会导致相似或更高的抗体效价。从儿科诊所招募的262名9-18岁的健康女性的存档血清进行了测试，以确定延迟给药间隔是否影响抗体亲和力。用改良的多重酶联免疫吸附试验测定受试者在接种前、后的亲和力指数(AI)。数据按给药间隔分组：(1)准时剂量2和3，(2)延迟剂量2和准时剂量3，(3)准时剂量2和延迟剂量3，(4)延迟剂量2和3。总体来说，HPV16的平均AI最高，HPV6的平均AI最低。就所有类型而言，所有延迟给药组在第三次给药后的平均AI均高于第三次给药组。在第三次给药后一个月，HPV6(ρ=0.25，p=0.0001)、HPV11(ρ=0.14，p=.0370)、HPV16(ρ=0.11，p=.0934)、和HPV18(ρ=0.37，p<；.0001)。我们的发现表明，较长的剂量间隔会导致更高的抗体亲和力，这进一步证明延迟注射4vHPV不会阻碍免疫反应。
The quadrivalent HPV vaccine (4vHPV) was originally recommended as a three-dose series (0/2/6 months), though delays in completing the series frequently occur. We previously found delayed dosing in girls resulted in similar or higher antibody titers compared to on-time dosing. Archived sera from 262 healthy females aged 9–18 recruited from pediatric clinics were tested to determine if delayed dosing intervals affected antibody avidity. Avidity index (AI; ratio of IgG Ab bound in the treated and untreated sample) was determined pre- and post-dose 3 4vHPV for each participant using a modified multiplex ELISA. Data were grouped by dosing intervals: (1) on-time dose 2 and 3, (2) delayed dose 2 and on-time dose 3, (3) on-time dose 2 and delayed dose 3, (4) delayed dose 2 and 3. Overall, mean AI was highest for HPV16 and lowest for HPV6. As expected, AI did not differ between groups 1 & 3 or groups 2 & 4 pre-dose 3, however, for most types mean AI was significantly higher both pre- and post-dose 3 for groups with delayed dose 2. For all types, mean AI was higher post-dose 3 in all delayed dosing groups compared to group 1. One month post-dose 3, there was a positive but weak correlation between AIs and antibody titer for HPV 6 (ρ = 0.25,p= .0001), HPV 11 (ρ = 0.14,p= .0370), HPV 16 (ρ = 0.11,p= .0934), and HPV 18 (ρ = 0.37,p< .0001). Our findings suggest longer intervals between doses result in higher antibody avidity, providing further evidence that delayed dosing of 4vHPV does not hinder the immune response.